ArticleMed (New York, N.Y.)2021
Tuberculosis endotypes to guide stratified host-directed therapy.
Article in Med (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis.The Journal of infectious diseases · 2026Article
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- A co-evolutionary perspective on humans andeLife · 2026Review
- Necro-mosaic: a lesion-aware framework for testing programmed cell-death-associated mechanisms in tuberculosis.Frontiers in immunology · 2026Review
- Proceedings from the Third International Post-Tuberculosis Symposium: expanding the circle.IJTLD open · 2025Article
- New drugs for the management of tuberculosis.Current opinion in infectious diseases · 2025Review
- Article
- Stool-Based Molecular Tuberculosis Treatment Monitoring: A Faster Means for Detecting Persistent Mycobacteria Compared to Phenotypic Culture.Open forum infectious diseases · 2025Article
- Regulatory Mechanisms of Co-Inhibitory Receptors in Tuberculosis Immunity: Implications for Therapeutic Targets.ImmunoTargets and therapy · 2025Review
- Association between blood inflammatory status and the survival of tuberculosis: a five-year cohort study.Frontiers in immunology · 2025Article
- Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.Frontiers in antibiotics · 2025Review
- Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium.American journal of respiratory and critical care medicine · 2024Review
- Artificial intelligence in tuberculosis: a new ally in disease control.Breathe (Sheffield, England) · 2024Article
- Interferon-Science (New York, N.Y.) · 2024Review
- Endotypes of Paediatric Cough-Do They Exist and Finding New Techniques to Improve Clinical Outcomes.Journal of clinical medicine · 2024Review
- Cell state transition analysis identifies interventions that improve control ofScience advances · 2023Article
- Predicting Pediatric Tuberculosis: The Need for Age-Specific Host Biosignatures.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Pediatric Post-TB Lung Disease: Ready for Prime Time?American journal of respiratory and critical care medicine · 2023Article
- Beyond the Clinic: The Activation of Diverse Cellular and Humoral Factors Shapes the Immunological Status of Patients with Active Tuberculosis.International journal of molecular sciences · 2023Review
- Cell state transition analysis identifies interventions that improve control ofbioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There is hope that host-directed therapy (HDT) for Tuberculosis (TB) can either shorten treatment duration, help cure drug resistant disease or limit the immunopathology. Many candidate HDT drugs have been proposed, however solid evidence only exists for a few select patient groups. The clinical presentation of TB is variable, with differences in severity, tissue pathology, and bacillary burden. TB clinical phenotypes likely determine the potential benefit of HDT. Underlying TB clinical phenotypes, there are TB "endotypes," defined as distinct molecular profiles, with specific metabolic, epigenetic, transcriptional, and immune phenotypes. TB endotypes can be characterized by either immunodeficiency or pathologic excessive inflammation. Additional factors, like comorbidities (HIV, diabetes, helminth infection), structural lung disease or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.